Caremibrain

ONCOVISION: caremibrain
ONCOVISION: caremibrain
ONCOVISION: caremibrain
Logotipo CareMiBrain

Innovation comes to Alzheimer disease.

Alzheimer’s disease (AD) is the most relevant neurodegenerative disease. Worldwide, nearly 36 million people have Alzheimer’s or a related dementia which will double every 20 years to 115.4 million in 2050, and in Europe affects about 7.5 million people (75% of all dementia cases) and is expected to increase up to 10.5 million in 2030, with a reported prevalence rate of 6.2% for all those aged 60 years and over. Only 1-in-4 people with AD have been diagnosed. For the fast ageing populations of the Western societies, AD is becoming one of the main public health concerns, associated with a social and economic burden, and the provision of care for people with AD is a complex and costly issue. At present, there is not any therapy that can effectively cure the disease since it is a complex disorder of which the exact cause is still not known.

The aproach to Alzheimer´s disease is changing gloabally. Oncovision’s plan, is to develop a new brain-dedicated PET that offers a valuable alternative to currently available whole-body PET systems.


Caremibrain fulfils the necessities of neurologists and nuclear physicists regarding the β-amyloid radiotracers and the firsts true effective drugs against Alzheimer disease in its final development stage (Aducanumab –Biogen–; Azeliragon –Pfizer–; Gantenerumab –Roche–, Solanezumab –Eli Lilly–, Verubecestat –Merck–).

The Hospital Clínico San Carlos leads a clinical trial to validate CareMiBrain with the focus on its commercialization in Europe at the end of this year. The clinical trial has two phases; the first one is done in exclusive in this public hospital of Madrid and is a descriptive, prospective and observational pilot study to compare and validate the image quality of the new PET in comparison to conventional WB-PET in 40 patients. For this task, two Nuclear Medicine physicians will compare and analyze separately, and without clinical information or previous diagnosis the results of the images provided by the conventional WB-PET and the dedicated brain PET.

Once this phase is validated and with CE mark for its comercial use, a new multicentric international study will start and will be lead by the Hospital Clínico San Carlos with 100 patients. Three others worldwide known hospital from Europe and United States as Tübingen Hospital in Germany, Massachussets General Hospital, in Boston; and Northern California PET Imaging Center, in Sacramento, will participate to reach a total of 310 patients. This clinical trial has received foundings from the European Union Horizon 2020 research and innovation program.

ONCOVISION: caremibrain benefits
ONCOVISION: caremibrain benefits
ONCOVISION: caremibrain benefits

Benefits


Very high resolution.

Its impressive resolution (under 2mm in all the FOV) and higher sensitivity generates high quality images with outstanding Signal/Noise ratio that could be used by doctors for reducing significantly the number of difficult to diagnose cases.

More patients studied per day.

At the same time, the higher sensitivity of the system allows to use a lower radiotracer dose and reducing scanning duration time, increasing the number of patients studied per day, their safety and comfort.

Totally transportable.

The small size of the equipment will allow physicians to us the technology in many clinics where large Medical devices can´t be install.

Precise image.

A dedicated Brain PET for Neurological patients will give an accurate image to determinate AD´s disease.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 711323.